#USA #NYU Langone #Mineola #Perlmutter Cancer Center #Anne Renteria

Perlmutter Cancer Center Enhances Leadership

The Perlmutter Cancer Center at NYU Langone Hospital—Long Island has made a significant addition to its leadership team with the appointment of Dr. Anne S. Renteria as the site director of its Transplantation and Cellular Therapy Center. Dr. Renteria previously held the role of medical director at MedStar Georgetown University Hospital, where she led their stem cell transplantation and cellular immunotherapy program. This appointment marks an exciting chapter for the center, as they continue their mission to provide accessible and state-of-the-art cancer treatments to their patients on Long Island.

Focus on Expansion and Care Coordination

Dr. Renteria's immediate priority will be to enhance and expand the already renowned blood cancer treatment programs at the Perlmutter Cancer Center. She will work closely with a dedicated team of healthcare professionals, including physicians, social workers, nutritionists, and transplant coordinators, aiming to deliver holistic and comprehensive patient care. The synergy between the Long Island site and the Bone Marrow Transplant Center located in Manhattan will facilitate coordinated research and clinical efforts that can ultimately benefit patients across both locations.

Dr. Renteria expressed her enthusiasm for the role, stating, "NYU Langone's continued mission to expand access to care for patients is what drew me to this position. Long Island has a large patient population, and we are positioned to provide them the state-of-the-art treatments for leukemias, lymphomas, myelomas, and transplant in their own neighborhoods."

Impressive Clinical Background

Additionally, Dr. Renteria serves as a clinical associate professor in the Department of Medicine at NYU Grossman Long Island School of Medicine. With an extensive research background, she has participated in over 40 clinical trials, particularly in the fields of Hematologic Malignancies and Hematopoietic Cell Therapies (HCT), including the innovative CAR-T cell therapies and both autologous and allogeneic HCT.

Furthermore, her previous roles demonstrate her leadership prowess. Dr. Renteria was a significant figure at various medical institutions where she established standards and contributed to clinical guidelines that enhanced patient care in stem cell transplants and management of graft-versus-host disease (GVHD).

Recognition and Professional Engagement

Her research findings are prominent in respected medical journals such as the Journal of Clinical Oncology, and she actively engages in the medical community as a member of notable organizations including the European Hematology Association and the American Society of Clinical Oncology. These connections not only reflect her commitment but also underscore the contributions she aims to make at the Perlmutter Cancer Center.

Future Prospects

As NYU Langone Health System continues to expand its outreach and improvement of patient services, Dr. Renteria's appointment is a strategic move that aligns with these goals. Her wealth of experience and passion for improving cancer care represents a substantial asset to the future of the Perlmutter Cancer Center.

The growing emphasis on providing integrated patient care locally is a testament to the center’s commitment to making high-quality medical treatments more accessible to the communities they serve. With Dr. Renteria at the helm, the Transplantation and Cellular Therapy Center is well-positioned to thrive and promote better health outcomes for cancer patients across Long Island.

• ---

For media inquiries, please contact Ryan Dziuba, Media Relations Manager at [email protected]